POSTER

                                                     27th Annual Meeting of the ISCP



                                      Safety of Antiplatelet Pretreatment in
                               Non-ST-segment Elevation Acute Coronary Syndrome

                         G Torres-Ruiz, P Rojas-Flores, P Carrion Montaner, E Bosch-Peligero and A Martínez-Rubio

                                   Hospital Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Spain.




   Citation: European Cardiology Review 2023;18:e26. DOI: https://doi.org/10.15420/ecr.2023.18.PO9

   Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial
   purposes, provided the original work is cited correctly.



Objectives: To determine the incidence of bleeding in patients with non-               We used logistic regression to identify variables associated with bleeding.
ST-segment elevation acute coronary syndrome (NST-ACS) after
antiplatelet pretreatment.                                                             Results: We included 172 consecutive patients (mean age, 68.7 years). All
                                                                                       received proton-pump inhibitors; 76,6% received antiplatelet
To determine the percentages of patients diagnosed with acute aortic                   pretreatment. Radial artery access was used for coronary angiography in
syndrome, pulmonary embolism, or stroke after pretreatment for initially               96,5%. Criteria for high bleeding risk were met by 39%.
misdiagnosed NST-ACS.
                                                                                       No major bleeding occurred. Only 4 (2,3%) patients had minor bleeding;
To analyse delays in coronary-artery bypass grafts (CABG) in relation to               all 4 had high bleeding risk, and 3 were undergoing treatment for cancer.
pretreatment.
                                                                                       Bleeding events were associated with high bleeding risk, active cancer,
Materials and methods: This prospective observational single-centre                    and low haemoglobin at admission (p<0,05).
study (June 2021–February 2022) included patients with NSTE-ACS
undergoing coronary angiography. This research has been approved by                    No cases of acute aortic syndrome, pulmonary embolism, or stroke were
an ethical committee.                                                                  observed. CABG was necessary in 11 (6.4%) patients, none of whom
                                                                                       required emergency surgery. Pretreatment did not delay CABG in any
Bleeding risk was assessed with ARC-HBR score. Patients were monitored                 patients.
in hospital for bleeding (TIMI and ISHT) criteria, acute aortic syndrome,
pulmonary embolism, and stroke. We analysed indications for emergency                  Conclusion: Pretreatment was safe and did not delay CABG. No cases
CABG and delays related to pretreatment.                                               were misdiagnosed as acute aortic syndrome, pulmonary embolism or
                                                                                       stroke.




                                                          © The Author(s) 2023. Published by Radcliffe Group Ltd.
                                                                           www.ECRjournal.com